Efifcacy of Cetuximab in Combination with Chemotherapy in Advanced Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2016.05.03
- VernacularTitle:西妥昔单抗联合化疗治疗晚期非小细胞肺癌的临床疗效分析
- Author:
YANG SHENG
1
;
WANG YAN
;
HU XINGSHENG
;
WANG HONGYU
;
HAO XUEZHI
;
XU JIANPING
;
WANG LIN
;
WANG BIN
;
LI JUNLING
;
ZHAO LONGMEI
;
JIANG PEIDI
;
QU FENGLIAN
;
ZHANG XIANGRU
;
SHI YUANKAI
Author Information
1. 100021北京，国家癌症中心/中国医学科学院北京协和医学院肿瘤医院内科，抗肿瘤分子靶向药物临床研究北京市重点实验室
- Keywords:
Lung neoplasms;
Cetuximab;
Targeted therapy;
Chemotherapy
- From:
Chinese Journal of Lung Cancer
2016;19(5):263-268
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Cetuximab is a monoclonal antibody directed against epidermal growth fac-tor receptor. Emerging evidence showed improved effcacy with the addition of cetuximab to chemotherapy in advanced non-small cell lung cancer (NSCLC), but the data in oriental population are limited. hTe aim of this study is to investigate the eff-cacy of cetuximab in combination with chemotherapy in Chinese patients with advanced NSCLC.Methods NSCLC patients receiving cetuximab in combination with chemotherapy in Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College were enrolled and retrospectively analyzed. Clinical characteristic, effcacy, outcome and toxicity data were analyzed.Results A total of 40 patients were enrolled into this study in which 29 were male, 36 with adenocarcinoma. In the 23 patients who had received palliative chemotherapy previously (with a median of 2 prior chemotherapy regimens), the median progression-free survival (PFS) atfer the last prior chemotherapy regimen was 2.3 months. For the overall population, 13 (32.5%) patients achieved partial response atfer cetuximab in combination with chemotherapy. Response rate were 52.9% (9/17) and 17.4% (4/23) in chemotherapy-naive patients and chemotherapy-treated patients, respectively (P=0.018). hTe median PFS was 4.8 months for the overall population. In chemotherapy-naive patients and chemotherapy-treated patients, the median PFS was 8.4 months and 4.1 months, respectively (P=0.062). hTe estimated median overall survival was 17.1 months. Toxicities were generally manageable and no treatment-related deaths occurred.Conclusion Cetuximab in addition to che-motherapy appears to be associated with promising effcacy and acceptable toxicity proifle in Chinese patients with advanced NSCLC. Further validation is needed.
